Zelda Therapeutics to Appear in CANNAINVESTOR Magazine & Webcast

ATLANTA, GA / ACCESSWIRE / February 21, 2017 / A leading Australian medicinal cannabis company, Zelda Therapeutics LTD. (ASX: ZLD, Zelda, or the Company) announced today that it has been featured in the February / March issue of the CANNAINVESTOR Magazine. To view the Company’s feature article in the CANNAINVESTOR Magazine, please visit www.cannainvestormag.com and subscribe for free on Wednesday, March 1, 2017. CANNAINVESTOR Magazine & Webcast is the leading industry magazine and webcast for cannabis investors, analysts and financial media.

In addition, Zelda Therapeutics will present on the Company’s activities on the CANNAINVESTOR Webcast (www.cannawebcast.com) on Thursday, February 23, 2017 at 4PM EST. Dr. Stewart Washer, Director of Zelda Therapeutics will deliver the online 30-minute presentation followed by 15-minutes of live Q&A. Cannabis investors, analysts, executives, media, and consumers who would like to attend the free online webcast, please click on the link www.cannawebcast.com and visit the Registration Page. After you register you will receive a link via e-mail to access the webcast on presentation day. To view the recorded presentation, please visit www.youtube.com and search for “Cannabis Investor Webcast”. The recorded presentation will be available two weeks after the live presentation.

“The CANNAINVESTOR Magazine and Webcast are digital platforms that will assist in lifting Zelda’s profile to better reach global audiences, increasing awareness on who we are and the valuable research we are undertaking. Zelda continues to focus on striving for excellence and maintaining our position as a leader in medical cannabis research, and in the development of natural medicines,” said Mr. Harry Karelis, Executive Chairman of Zelda Therapeutics.

About Zelda Therapeutics LTD. (www.zeldatherapeutics.com)

Zelda Therapeutics (“Zelda”) is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (Aunt Zelda’s) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer. It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar program is in place with the Australian Telethon Kids Institute targeting pediatric brain cancer and Curtin University targeting pancreatic cancer.

Safe Harbor Statement

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues as well as any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the Securities and Exchange Commission. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory.

Corporate

Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr. Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Media

Andrew Ramadge
Media & Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

SOURCE: CANNAINVESTOR Magazine

ReleaseID: 455598